Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Osteonecrosis of the jaw does not belong to the known adverse drug reactions of Forsteo and is not listed in the summary of product characteristics.1
Teriparatide has an anabolic effect on bone, which is different than the mechanism of action of antiresorptive therapies, such as bisphosphonates.2
Among the pivotal Lilly-sponsored teriparatide clinical trials for the treatment of osteoporosis, ONJ was not reported as a treatment-emergent adverse event (TEAE).3
In the Lilly teriparatide spontaneous reporting database, which contains data as of September 12, 2019, both “osteonecrosis” and “osteonecrosis of the jaw” have been very rarely reported.3
To date, there have been no published case reports of the development of ONJ during treatment with teriparatide.
Based on of the available information, teriparatide does not appear to be causally associated with osteonecrosis of the jaw.
1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905-916. http://dx.doi.org/10.1056/NEJMra067395
3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Datum fӧr senaste ӧversyn 2020 M03 05